Elamipretide (SS-31): the first FDA-approved mitochondrial peptide
On September 19, 2025, a four-amino-acid peptide became the first approved drug to directly target the inside of a mitochondrion.
That sentence probably doesn’t sound as consequential as it is. So let’s unpack it.
—
## What is elamipretide?
Elamipretide — also known as SS-31, MTP-131, and by the brand name Stealth — is a synthetic tetrapeptide: four amino acids (D-Arg–Dmt–Lys–Phe-NH₂) linked in a specific sequence. It was developed by Stealth BioTherapeutics, building on work by Hazel Szeto and Peter Schiller at Cornell University.
What makes it unusual is where it goes: through the outer mitochondrial membrane and directly into contact with the inner membrane, a feat that most molecules simply cannot achieve. Once there, it has a very specific job.
—
## The cardiolipin connection
Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane. It serves as the scaffold for the respiratory chain supercomplexes — the molecular machinery that converts nutrients into ATP, the cell’s energy currency.
Think of cardiolipin as the molecular glue holding the powerhouse together. When it’s oxidised or degraded (as happens in disease and, progressively, with age), the supercomplexes begin to disassemble. Electron transport becomes inefficient. Reactive oxygen species (ROS) accumulate. Energy output drops.
Elamipretide binds to cardiolipin with high affinity and protects it. The result, according to preclinical and clinical data:
– Stabilised respiratory chain supercomplexes — the energy machinery holds together
– Enhanced electron transport efficiency — more ATP per unit of substrate
– Reduced ROS production — less oxidative damage downstream
A targeted intervention at the molecular root of mitochondrial dysfunction.
—
## The FDA approval: what it was for
The September 2025 accelerated approval was for Barth syndrome (BTHS) — a rare X-linked mitochondrial disorder affecting males, caused by mutations in the tafazzin gene. Tafazzin is responsible for remodelling cardiolipin, so patients with BTHS have structurally abnormal cardiolipin from birth. The result: severe cardiomyopathy, skeletal myopathy, and neutropenia, with no cure.
Elamipretide’s pivotal trial was a randomised, double-blind, placebo-controlled crossover design that showed modest results on primary endpoints (6-minute walk test, fatigue scores). The open-label extension — running 168 weeks, over three years — showed sustained clinical benefit in patients who continued treatment. The FDA granted accelerated approval on the strength of that extended data, with a confirmatory trial required.
It is the first time a drug has been approved for directly targeting mitochondrial biology.
—
## Why this matters beyond Barth syndrome
Barth syndrome affects an estimated 1 in 300,000 to 400,000 male births. By any definition, a niche indication.
But elamipretide’s significance to the broader field isn’t about Barth syndrome. It’s about what the approval demonstrates: you can engineer a peptide to get inside a mitochondrion, hit a specific molecular target, and produce measurable clinical benefit.
That’s not a small thing. Mitochondria are notoriously difficult to drug. They have two membranes, tight electrochemical gradients, and strict quality-control machinery that excludes most molecules. Getting a therapeutic into the inner membrane and having it do something useful — safely, over years — is technically formidable.
Elamipretide has been studied in a range of conditions beyond BTHS, precisely because mitochondrial dysfunction runs through so many diseases:
– **Heart failure with reduced ejection fraction**: Phase 2 data showed improvements in mitochondrial respiration and cardiac function
– **Primary mitochondrial myopathy**: Benefits in exercise tolerance
– **Diabetic cardiomyopathy**: Protective effects in animal models
– **Age-related macular degeneration (dry AMD)**: Cardiolipin is abundant in photoreceptors; early clinical data are encouraging
– **Sarcopenia**: Mitochondrial decline in ageing muscle is a core driver
—
## The ageing angle
Mitochondrial dysfunction is one of the most well-characterised hallmarks of ageing, identified in the landmark 2013 Hallmarks of Aging paper and its 2023 revision. As we age, cardiolipin content in mitochondrial membranes declines, respiratory chain supercomplexes destabilise, ATP production in muscle, brain, and cardiac cells drops, and ROS production increases.
This isn’t a rare-disease problem. It’s the universal biology of ageing. Elamipretide — or a future generation of cardiolipin-targeted peptides — is directly relevant to that.
—
## How it fits with the mitochondrial peptide family
Readers of Amino Research will recognise the mitochondrial peptide theme. We covered MOTS-c recently — a peptide encoded directly in mitochondrial DNA that signals between mitochondria and the nucleus, regulating metabolism and stress response.
Elamipretide takes a different approach. Rather than being a signalling peptide, it’s a structural protectant — it physically stabilises the mitochondrial membrane architecture that MOTS-c and other mitochondrial-encoded peptides depend on to function.
The two approaches are complementary:
| | **Elamipretide / SS-31** | **MOTS-c** |
|—|—|—|
| Origin | Synthetic (designed) | Encoded in mitochondrial DNA |
| Mechanism | Binds cardiolipin, stabilises respiratory chain | Nuclear gene regulation, metabolic signalling |
| Target | Inner mitochondrial membrane structure | Whole-body metabolic homeostasis |
| Stage | FDA-approved (rare disease) | Preclinical / early research |
| Key effect | Reduces ROS, improves ATP output | Improves insulin sensitivity, stress resilience |
—
## What to watch
The FDA approval triggers a confirmatory trial requirement. Results will matter both for Barth syndrome patients and for the broader case that mitochondria-targeted peptides work in humans.
Research programmes for elamipretide in heart failure, AMD, and sarcopenia are all ongoing. Positive Phase 3 data in any of those larger populations would substantially validate the cardiolipin-targeted approach as something more than a rare-disease treatment.
—
## Summary
Elamipretide (SS-31) achieved something researchers have been working toward for decades: regulatory proof that a peptide engineered to target mitochondrial biology can deliver measurable clinical benefit. The specific approval is for Barth syndrome, but the mechanism — cardiolipin binding, respiratory chain stabilisation, ROS reduction — maps directly onto the universal biology of ageing.
The rare-disease approval is, in some ways, the smallest part of the story.
—
*Source: Yasuda T, et al. “Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.” Drug Discoveries & Therapeutics. 2026 Jan. PMID: 41260682.*
*This article is produced for research and educational purposes. Elamipretide is a prescription therapeutic approved for a specific rare disease. Nothing here constitutes medical advice.*